AtriCure Announces Launch of the cryoFORM™ Cryoablation Probe
Offering expands on the company’s cryoablation suite of products by introducing an even more flexible probe for use in a variety of surgical interventions to treat cardiac arrhythmias
The cryoFORM™ probe builds off of the company’s core strengths in cryoablation technology, leveraging such important features as thermal capacity to remove heat and active defrost, which allows the probe to be safely and quickly detached while maintaining the tissue’s frozen state. Building upon those strengths, the new probe offers increased flexibility, allowing the surgeon to more easily manipulate and apply the device and conform to challenging anatomies.
“We are excited to announce the launch of the cryoFORM™ probe,” said
The development of the cryoFORM™ probe is also intended to address the trend towards more minimally invasive techniques in cardiac surgery, which are being used in conjunction with a variety of cardiac therapies, including mitral and aortic valve repair. In addition to an even more malleable probe shaft, the cryogen supply tubing for the cryoFORM™ probe has been made more flexible to allow for easier handling and delivery, which improves the overall ease-of-use in settings where range of motion is limited.
Cryoablation technology has been used for decades in the treatment of cardiac arrhythmias, and has advantages over other energy sources for creating lesions on certain cardiac structures. The entire cryoICE™ system offers exceptional cryo ablation performance by leveraging nitrous oxide, which is the most widely used and published cryogen in all cardiac specialties. Nitrous oxide combined with the unique design of the probe ensures rapid extraction of heat from targeted tissue, one of the primary determinants of success in cryo ablation. This rapid heat extraction combine with a slow and natural thawing process called active defrost, provides maximum cell death of targeted tissues.
“The cryoFORM probe works well in MI-MVR procedures and allows me to
easily shape and position the probe inside the LA using endoscopic
instruments,” said
The cryoFORM™ probe has received CE mark and is pending
About AtriCure
View source version on businesswire.com: http://www.businesswire.com/news/home/20150930005252/en/
Source:
AtriCure, Inc.
Valerie Storch-Willhaus, 612-605-3311
Media
Relations
Director, Corporate Marketing and Communications
vstorch-willhaus@atricure.com
or
Andy
Wade, 513-755-4564
Investor Relations
Senior Vice President
and Chief Financial Officer
awade@AtriCure.com